This Treatment Cuts Migraine Days in Diverse Populations

Analysis of the COMPEL study shows that onabotulinumtoxinA (Botox) can help reduce migraine days, lower migraine-related disability, and improve quality of life in diverse populations of chronic migraine patients. Molly O'Brien breaks down the data in this Migraine Minute News Update. Read More: https://bit.ly/4trLxyK Researchers acknowledge that the term "race" doesn't accurately capture diverse cultural differences, noting that future research should distinguish between race and ethnicity. *This content is not sponsored and is intended for educational purposes only. It does not constitute an endorsement by the Association of Migraine Disorders for BOTOX® products.